[{"address1": "650 Castro Street", "address2": "Suite 450", "city": "Mountain View", "state": "CA", "zip": "94041", "country": "United States", "phone": "650 200 0412", "website": "https://www.altoneuroscience.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.", "fullTimeEmployees": 76, "companyOfficers": [{"maxAge": 1, "name": "Dr. Amit  Etkin M.D., Ph.D.", "age": 47, "title": "Founder, Chairman of the Board, CEO & President", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 995998, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nicholas C. Smith", "age": 35, "title": "CFO & Chief Business Officer", "yearBorn": 1989, "fiscalYear": 2024, "totalPay": 680467, "exercisedValue": 0, "unexercisedValue": 217377}, {"maxAge": 1, "name": "Mr. Michael C. Hanley M.B.A.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 623006, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Segal B.Sc. (Hons), BCom, CA, MSc", "age": 62, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1962, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin R. McQuade J.D.", "age": 49, "title": "General Counsel, Chief Administrative Officer & Corporate Secretary", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Savitz M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 579569, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Powell", "age": 49, "title": "Chief Development Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.3, "open": 2.32, "dayLow": 2.27, "dayHigh": 2.4, "regularMarketPreviousClose": 2.3, "regularMarketOpen": 2.32, "regularMarketDayLow": 2.27, "regularMarketDayHigh": 2.4, "payoutRatio": 0.0, "forwardPE": -0.81881535, "volume": 83674, "regularMarketVolume": 83674, "averageVolume": 298811, "averageVolume10days": 570360, "averageDailyVolume10Day": 570360, "bid": 2.1, "ask": 2.59, "bidSize": 3, "askSize": 11, "marketCap": 63619432, "fiftyTwoWeekLow": 1.6, "fiftyTwoWeekHigh": 17.55, "fiftyDayAverage": 2.4522, "twoHundredDayAverage": 4.54495, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -74757320, "profitMargins": 0.0, "floatShares": 17903611, "sharesOutstanding": 27072100, "sharesShort": 2793266, "sharesShortPriorMonth": 3008421, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.103199996, "heldPercentInsiders": 0.07481, "heldPercentInstitutions": 0.77522004, "shortRatio": 11.63, "shortPercentOfFloat": 0.131, "impliedSharesOutstanding": 27072100, "bookValue": 5.138, "priceToBook": 0.4573764, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -63183000, "trailingEps": -2.3, "forwardEps": -2.87, "enterpriseToEbitda": 1.078, "52WeekChange": -0.80497926, "SandP52WeekChange": 0.12677538, "quoteType": "EQUITY", "currentPrice": 2.35, "targetHighPrice": 17.34, "targetLowPrice": 4.0, "targetMeanPrice": 11.33429, "targetMedianPrice": 10.0, "recommendationMean": 1.375, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 160754000, "totalCashPerShare": 5.938, "ebitda": -69324000, "totalDebt": 26438000, "quickRatio": 22.152, "currentRatio": 22.533, "debtToEquity": 19.007, "returnOnAssets": -0.22883, "returnOnEquity": -0.38039002, "freeCashflow": -39361376, "operatingCashflow": -52997000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ANRO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Alto Neuroscience, Inc.", "messageBoardId": "finmb_1675972978", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.173911, "regularMarketPrice": 2.35, "marketState": "CLOSED", "postMarketChangePercent": 2.1148946, "postMarketPrice": 2.3997, "postMarketChange": 0.04970002, "regularMarketChange": 0.049999952, "regularMarketDayRange": "2.27 - 2.4", "fullExchangeName": "NYSE", "averageDailyVolume3Month": 298811, "fiftyTwoWeekLowChange": 0.7499999, "fiftyTwoWeekLowChangePercent": 0.4687499, "fiftyTwoWeekRange": "1.6 - 17.55", "fiftyTwoWeekHighChange": -15.199999, "fiftyTwoWeekHighChangePercent": -0.86609685, "fiftyTwoWeekChangePercent": -80.497925, "earningsTimestampStart": 1755201600, "earningsTimestampEnd": 1755201600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.3, "epsForward": -2.87, "fiftyDayAverageChange": -0.10220003, "fiftyDayAverageChangePercent": -0.041676875, "twoHundredDayAverageChange": -2.19495, "twoHundredDayAverageChangePercent": -0.48294264, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1706884200000, "corporateActions": [], "postMarketTime": 1751573353, "regularMarketTime": 1751562002, "exchange": "NYQ", "displayName": "Alto Neuroscience", "trailingPegRatio": null, "__fetch_time": "2025-07-05"}]